Crystal Snider, MD
Family Medicine · Kewanee, ILNPI 1700098845
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $432 and has fallen 81.4% since, to $80 in 2024.
Across 121 payments — averaging $14.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$326
- Pfizer$222
- AstraZeneca$204
- Novartis$152
- Amgen$146
- E.r. Squibb & Sons, L.L.C.$65
- plus $699 from 23 others
What the payments were for
- Food & beverage$1,812100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $326 |
| Pfizer | 24 | $222 |
| AstraZeneca | 14 | $204 |
| Novartis | 9 | $152 |
| Amgen | 10 | $146 |
| E.r. Squibb & Sons, L.L.C. | 4 | $65 |
| Supernus Pharmaceuticals, Inc. | 3 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $60 |
| Genentech USA, Inc. | 3 | $53 |
| Novo Nordisk | 3 | $50 |
| Bayer | 3 | $44 |
| Exact Sciences | 3 | $42 |
| Abbott | 2 | $36 |
| Boehringer Ingelheim | 2 | $35 |
| Ceribell, Inc. | 1 | $34 |
| Organon | 2 | $34 |
| Lilly USA, LLC | 2 | $30 |
| Dexcom, Inc. | 1 | $28 |
| Corium, LLC | 1 | $27 |
| Almatica Pharma LLC | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Exeltis, USA Inc. | 1 | $14 |
| Inogen, Inc. | 1 | $12 |
| Ironshore Pharmaceuticals Inc. | 1 | $11 |
How this compares
$1,812 in reported general payments places this provider in the 80th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 13 | $463 |
| Levothyroxine Sodium | 26 | $393 |
| Naproxen | 13 | $321 |
| Escitalopram Oxalate | 12 | $297 |
| Famotidine | 12 | $224 |
| Metformin Hcl ErMetformin Hcl | 13 | $183 |
| Hydrochlorothiazide | 12 | $134 |
| Cyclobenzaprine Hcl | 12 | $104 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Kewanee
- Frank PhillipsChicago$1.6M
- Peter TothSterling$1.4M
- Bradley TorphyChicago$1.3M
- Jeffrey RoyceRockford$890K
- Anthony AuriemmaWestmont$788K
- Manfred ManGurnee$764K
- Barbara BellarOakbrook Terrace$599K
- Bernie RancheroAltamont$533K
- Sandy GibsonChicago$309K
- Mandy GittlerChicago$204K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.